NASDAQ:NVCR

NovoCure Stock Forecast, Price & News

$128.36
+1.16 (+0.91 %)
(As of 09/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$126.59
$129.65
50-Day Range
$126.07
$190.00
52-Week Range
$100.13
$232.76
Volume315,292 shs
Average Volume793,725 shs
Market Capitalization$13.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
30 days | 90 days | 365 days | Advanced Chart
Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.


NovoCure logo

About NovoCure

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Headlines

NovoCure is Now Oversold (NVCR) - Nasdaq
NovoCure is Now Oversold (NVCR) - Nasdaq
September 14, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

408th out of 1,352 stocks

Surgical & Medical Instruments Industry

40th out of 123 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view top-rated stocks.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NovoCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for NovoCure
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings data on Thursday, July, 29th. The medical equipment provider reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.02 by $0.16. The medical equipment provider had revenue of $133.52 million for the quarter, compared to analyst estimates of $141.50 million. NovoCure had a negative net margin of 0.84% and a negative trailing twelve-month return on equity of 1.18%.
View NovoCure's earnings history
.

How has NovoCure's stock price been impacted by COVID-19 (Coronavirus)?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 90.5% and is now trading at $128.36.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NVCR?

6 brokers have issued 1 year price objectives for NovoCure's shares. Their forecasts range from $142.00 to $250.00. On average, they expect NovoCure's stock price to reach $186.14 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Wilhelmus C. M. Groenhuysen, Chief Operating Officer
  • Ashley Cordova, Chief Financial Officer
  • Uri Weinberg, Chief Science Officer
  • Ely Benaim, Chief Medical Officer (LinkedIn Profile)

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Who are some of NovoCure's key competitors?

What other stocks do shareholders of NovoCure own?

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (9.28%), Baillie Gifford & Co. (8.99%), Capital International Investors (8.82%), Vanguard Group Inc. (7.53%), BlackRock Inc. (6.29%) and State Street Corp (2.17%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure
.

Which major investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Morgan Stanley, Morgan Stanley, Credit Suisse AG, Renaissance Technologies LLC, Mitsubishi UFJ Trust & Banking Corp, and JPMorgan Chase & Co.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which major investors are buying NovoCure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Frontier Capital Management Co. LLC, Citigroup Inc., Price T Rowe Associates Inc. MD, Macquarie Group Ltd., State Street Corp, and Invesco Ltd..
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $128.36.

How much money does NovoCure make?

NovoCure has a market capitalization of $13.30 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,023 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

Where are NovoCure's headquarters?

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 441534756700 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.